MedTrace Logo

Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease

NCT00976430 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-08-14

No results posted yet for this study

Summary

This study is intended to look at the safety and efficacy of the use of autologous bone marrow derived stem cell transplant in patients with advanced Parkinson's disease.

Conditions

Interventions

PROCEDURE

Autologous Bone marrow derived stem cells transplant

Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.

Sponsors & Collaborators

  • Jaslok Hospital and Research Centre

    lead OTHER

Principal Investigators

  • Paresh k Doshi, MCh · Incharge Stereotactic and functional Neurosurgery,Jaslok Hospital and Research Centre.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-11-30
Completion
2012-04-30

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976430 on ClinicalTrials.gov